Clinical Trial Update: Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation [Phase 2]

View source ↗

Summary

Update on a Phase 2 trial evaluating camostat mesylate for protein-losing enteropathy after Fontan operation. The study status is COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Protein-losing Enteropathy

Drugs mentioned

• Camostat Mesylate (camostat mesylate)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Fontan Operation, Protein-Losing Enteropathy | Phase 2 | Status: COMPLETED